Stockscreener 앱 받기
16.05
3.43%
-0.57
시간 외 거래:
15.91
-0.14
-0.87%
전일 마감가:
$16.62
열려 있는:
$16.61
하루 거래량:
81,019
Relative Volume:
1.17
시가총액:
$874.56M
수익:
-
순이익/손실:
$-143.59M
주가수익비율:
-5.6842
EPS:
-2.8236
순현금흐름:
$-119.47M
1주 성능:
-4.01%
1개월 성능:
-13.99%
6개월 성능:
-17.78%
1년 성능:
-2.73%
1일 변동 폭
$15.91
$16.88
1주일 범위
$15.91
$18.00
52주 변동 폭
$11.51
$25.50
Pharvaris Nv Stock (PHVS) Company Profile
PHVS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PHVS
Pharvaris Nv
|
16.05 | 911.13M | 0 | -143.59M | -119.47M | -2.8236 |
|
ONC
Beone Medicines Ltd Adr
|
257.00 | 26.69B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.82 | 114.81B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.282 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
85.54 | 6.60B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
483.07 | 65.36B | 14.09B | 4.50B | 2.96B | 39.28 |
Pharvaris Nv Stock (PHVS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-09-25 | 개시 | Wedbush | Outperform |
| 2023-08-15 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-10-05 | 개시 | Bryan Garnier | Buy |
| 2022-09-13 | 재개 | JMP Securities | Mkt Outperform |
| 2022-08-23 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-22 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-05-25 | 개시 | JMP Securities | Mkt Outperform |
| 2021-03-02 | 개시 | BofA Securities | Neutral |
| 2021-03-02 | 개시 | Morgan Stanley | Overweight |
| 2021-03-02 | 개시 | Oppenheimer | Outperform |
| 2021-03-02 | 개시 | SVB Leerink | Outperform |
모두보기
Pharvaris Nv 주식(PHVS)의 최신 뉴스
Pharvaris (PHVS) Receives Continued "Outperform" Rating from Wedbush | PHVS Stock News - GuruFocus
Citizens JMP reiterates Market Outperform rating for Pharvaris stock By Investing.com - Investing.com UK
Transcript : Pharvaris N.V.Special Call - marketscreener.com
Pharvaris reports promising results for deucrictibant in HAE By Investing.com - Investing.com UK
Pharvaris (NASDAQ:PHVS) Shares Acquired by Deutsche Bank AG - Defense World
Northern Trust Corp Purchases 76,188 Shares of Pharvaris (NASDAQ:PHVS) - Defense World
How To Trade (PHVS) - news.stocktradersdaily.com
Cubist Systematic Strategies LLC Purchases New Holdings in Pharvaris (NASDAQ:PHVS) - Defense World
New Clinical Data Reveals Long-Term Success of Oral HAE Treatment Deucrictibant - Stock Titan
Pharvaris (NASDAQ:PHVS) Shares Gap Down – Here’s What Happened - Defense World
Brokers Offer Predictions for Pharvaris FY2025 Earnings - Defense World
Q2 Earnings Forecast for Pharvaris Issued By Leerink Partnrs - Defense World
Cantor Fitzgerald Cuts Pharvaris (NASDAQ:PHVS) Price Target to $25.00 - Defense World
Research Analysts Issue Forecasts for Pharvaris Q2 Earnings - Defense World
Pharvaris (NASDAQ:PHVS) Holdings Decreased by Barclays PLC - Defense World
The Manufacturers Life Insurance Company Reduces Stake in Pharvaris (NASDAQ:PHVS) - Defense World
Pharvaris (NASDAQ:PHVS) Shares Down 5.1% on Disappointing Earnings - Defense World
Transcript : Pharvaris N.V. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 08 - marketscreener.com
PHVS Reports Decrease in Cash Reserves by March Quarter End | PH - GuruFocus
Pharvaris (PHVS) Target Price Revised by Cantor Fitzgerald | PHV - GuruFocus
Pharvaris (PHVS) Target Price Increased by Wedbush Amid Clinical Progress | PHVS Stock News - GuruFocus
Wedbush Adjusts Pharvaris Price Target to $17 From $25, Maintains Outperform Rating - marketscreener.com
(PHVS) Long Term Investment Analysis - news.stocktradersdaily.com
Pharvaris Reports First Quarter 2025 Financial Results and Provides Business Update - marketscreener.com
Pharvaris Hits Major FDA Milestone for HAE Drug Pipeline While Phase 3 Trials Show Strong Progress - Stock Titan
Pharvaris (PHVS) Expected to Announce Earnings on Wednesday - Defense World
Pharvaris to Host a Virtual R&D Call “Deucrictibant: Beyond HAE Type 1/2” on June 4 - Stock Titan
Pharvaris (NASDAQ:PHVS) Shares Acquired by JPMorgan Chase & Co. - Defense World
When (PHVS) Moves Investors should Listen - news.stocktradersdaily.com
Pharvaris NV expected to post a loss of 76 cents a shareEarnings Preview - TradingView
Geode Capital Management LLC Has $735,000 Stock Position in Pharvaris (NASDAQ:PHVS) - Defense World
Pharvaris (NASDAQ:PHVS) Holdings Increased by Legal & General Group Plc - Defense World
Pharvaris (NASDAQ:PHVS) Research Coverage Started at Cantor Fitzgerald - Defense World
Analysts Offer Predictions for Pharvaris FY2025 Earnings - Defense World
Cantor Fitzgerald Initiates Pharvaris at Overweight With $28 Price Target - marketscreener.com
JMP reiterates Pharvaris stock with $55 target, positive outlook By Investing.com - Investing.com UK
Where are the Opportunities in (PHVS) - news.stocktradersdaily.com
What is Leerink Partnrs’ Forecast for Pharvaris Q1 Earnings? - The AM Reporter
5,800 Shares in Pharvaris (NASDAQ:PHVS) Acquired by KLP Kapitalforvaltning AS - Defense World
What is Leerink Partnrs’ Estimate for Pharvaris Q1 Earnings? - Defense World
Wedbush Issues Pessimistic Forecast for Pharvaris Earnings - Defense World
What is Wedbush’s Forecast for Pharvaris FY2029 Earnings? - Defense World
Pharvaris NV reports results for the quarter ended December 31Earnings Summary - TradingView
Pharvaris Reports 2024 Financial Results and Business Progress - TipRanks
Pharvaris Accelerates HAE Drug Development: Phase 3 Trial Fully Enrolled, €281M War Chest - Stock Titan
Pharvaris (PHVS) Projected to Post Earnings on Wednesday - Defense World
(PHVS) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Pharvaris Says EU Orphan Designation Received for Deucrictibant - MarketScreener
Major EU Breakthrough: Pharvaris' Angioedema Drug Gains Coveted Orphan Status - Stock Titan
(PHVS) Technical Data - news.stocktradersdaily.com
Can Pharvaris Impress Investors at Upcoming Leerink Conference? - StockTitan
Pharvaris Nv (PHVS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.86%
1.24%
자본화:
|
볼륨(24시간):